Marketing PRP therapy means working inside four overlapping rulebooks at once: the FDA, the FTC, the ad platforms, and your state. Break any one and you risk warning letters, ad bans, or worse. This guide walks each channel, what it prohibits, what it permits, and what it means for your PRP marketing copy. It ends with a safe harbor framework that satisfies all of them at once.
TLDR: PRP marketing is governed by four layers that all apply at the same time: FDA product rules, FTC substantiation rules, ad platform policies, and state law. The FDA controls what your language implies about the product. The FTC controls what proof you need for claims. Google and Meta restrict how you advertise. States can add their own notice rules. This guide covers each layer and ends with a safe harbor messaging approach that stays inside all of them. None of this is legal advice. Confirm your specifics with qualified counsel.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing company, not a law firm or compliance consultancy.
Most PRP marketing problems do not come from bad intent. They come from a clinic following one rulebook while breaking another it did not know existed. You write copy that sounds fine to you, it passes your own gut check, and then an ad gets rejected or a letter shows up. The rules were there the whole time. You just could not see all four at once.
That is the real challenge with PRP marketing. It is not one set of rules. It is four, layered on top of each other, each written by a different authority with a different goal. A phrase that satisfies the FTC can still violate a Google policy. A page that is fine federally can miss a state notice rule. To market PRP safely, you have to see all four layers together.
This guide lays them out one at a time, then shows how to write copy that satisfies all of them. Treat it as the master reference. The individual channel posts on this site go deeper on each piece, and we will link to them as we go.
The Four Layers Of PRP Marketing Compliance
PRP marketing sits under four rule sets that apply at the same time: FDA product classification, FTC advertising standards, ad platform policies, and state law. Each controls a different part of your marketing. You have to satisfy all four, not pick one.
Here is the map before we go layer by layer.
| Layer | Who Sets It | What It Controls |
|---|---|---|
| FDA | Federal | What your language can imply about the product |
| FTC | Federal | What proof you need behind any claim |
| Ad platforms | Google, Meta | How and whether you can advertise |
| State law | Each state | Extra notice and disclosure rules |
What this means for your practice: A compliance check is not one question. It is four. Before any PRP marketing goes live, it should pass the FDA test, the FTC test, the platform test, and the state test. Most clinics check one and assume the rest.
Let us start with the layer that shapes your language the most.
Layer One: FDA Product Classification (361 vs. 351)
The FDA does not regulate your marketing directly, but it regulates your product, and your marketing language can change how the product is classified. This is the 361 versus 351 distinction, and it is the foundation of PRP compliance.
Here is the core idea in plain terms. The FDA sorts human cell and tissue products into two buckets. Section 361 products are low-risk, minimally manipulated, and used for the same basic function they had in the body. They do not need pre-market approval. Section 351 products are treated as drugs or biologics and require full FDA approval before marketing. PRP, when it is autologous and minimally manipulated, generally falls under the 361 pathway.
Here is the trap. What pushes a product from 361 into 351 territory is often the claim, not the product. If your marketing implies the product diagnoses, treats, cures, or prevents a disease, you can move it into drug territory in the eyes of the FDA. The product did not change. Your words did. Our deeper breakdown of the 361 vs. 351 distinction for regen marketers walks through exactly where that line sits.
This is not theoretical. There was a documented increase in FDA warning letters in 2025 tied to companies’ marketing claims on their websites and promotional materials. You can review enforcement actions on the FDA’s public warning letters database.
What this means for your practice: Your PRP marketing language is a regulatory act, not just a marketing one. Describe the process and the procedure. Do not let your copy imply the product treats a disease, because that single shift can change what your product legally is.
That sets up the second federal layer, which governs proof.
Layer Two: FTC Substantiation Rules
The FTC governs advertising claims, and its core rule is simple to state and hard to meet: every claim must be truthful and backed by solid evidence before you publish it. For health claims, that bar is high.
The FTC’s 2022 Health Products Compliance Guidance is the controlling reference. It applies to all health-related product advertising and lays out what counts as adequate proof. The guidance is clear that health benefit claims generally need competent and reliable scientific evidence, often in the form of well-designed human clinical testing. You can read it directly on the FTC’s health products compliance guidance page.
For PRP, the practical takeaway is about restraint. You can describe what PRP is and how the procedure works. You cannot claim benefits you cannot back with real evidence. Overstating early or limited research is a classic FTC problem, and words like “promising” or “proven” carry weight you may not be able to support.
There is also a testimonial dimension. Reviews and patient statements are advertising claims in the FTC’s eyes. They must be genuine, disclose any material connection, and not imply typical results that are not typical.
What this means for your practice: The FTC question is always “can you prove it?” If a claim would require evidence you do not have, do not make the claim. Describe the process honestly and let the consultation handle the rest.
With the federal layers set, the next two are about where and how you can actually run ads.
Layer Three: Ad Platform Policies (Google And Meta)
Google and Meta set their own rules, and they are stricter than federal law in important ways. Both restrict regenerative medicine advertising, and PRP is specifically caught in Google’s net. These are private policies, so the platforms enforce them however they choose.
Google Ads
Google’s Healthcare and medicines policy prohibits advertising for speculative or experimental medical treatments. The named examples include stem cell therapy, gene therapy, other forms of regenerative medicine, and platelet rich plasma. In other words, you cannot run a Google ad that directly promotes PRP as a treatment.
There is a path, though. Google allows educational and informational content under certain conditions, which gives clinics a real way to advertise without promoting the treatment directly. Google also now states that policy violations do not lead to immediate suspension without warning, and that a warning is issued at least seven days before any account suspension. The full mechanics are covered in our guides to running Google Ads for regenerative medicine and marketing PRP when Google restricts your ads.
Meta Ads
Meta works differently. Its 2025 changes were mostly about data and targeting, not just claim language. Meta moved health and wellness into a sensitive category, which limited how advertisers target users and track conversions. Practices can no longer target users based on health conditions, and lower-funnel optimization got restricted. On top of that, Meta’s standard content rules still bar before-and-after imagery and personal health claims.
So the Meta challenge for PRP is two-sided: a content layer (what you can say and show) and a data layer (how you can target and measure). Our breakdown of Meta’s health ad restrictions and the question of running Facebook ads for PRP covers both.
What this means for your practice: The platforms are where good federal compliance still gets you rejected. Google bans direct PRP promotion but allows education. Meta limits your data and your imagery. You can advertise within both, but only if you understand that platform rules are a separate test from federal law.
The fourth layer changes depending on where you practice.
Layer Four: State Advertising Law
State law adds a fourth layer that varies by location. Some states impose specific notice or disclosure rules on regenerative marketing that go beyond federal requirements. You have to know your own state’s rules, because they can add mandatory language to your ads.
Florida is the clearest current example. The state’s law CS/CS/SB 1768 took effect on July 1, 2025. It allows physicians to perform certain stem cell therapies not approved by the FDA for orthopedic conditions, wound care, and pain management, and it adds marketing requirements. The law requires a specific notice in any advertisement for these therapies, and a signed informed consent disclosing that the therapy is not FDA approved. You can confirm the details on the Florida Senate page for SB 1768.
One precise point matters here. The Florida statute targets stem cell therapy specifically, not PRP. We include it for two reasons. It is the clearest example of how a state can layer extra advertising rules onto regenerative marketing. And many clinics that market PRP also market stem cell services that the law does reach. Do not assume it applies to PRP, and do not assume your state has nothing. Check.
What this means for your practice: Federal compliance is not the finish line. Your state may require notice language, consent steps, or disclosures that change your ad copy directly. This is a question for local counsel, because the rules differ by state and change often.
That leaves one more channel that has its own rulebook.
Email Marketing: CAN-SPAM And HIPAA
Email is its own compliance channel for PRP marketing, governed by CAN-SPAM and shadowed by HIPAA. The rules are manageable, but they are specific, and “it is just an email” is not a defense.
CAN-SPAM sets the basics for commercial email: accurate sender and subject lines, a physical mailing address, and a clear, honored opt-out. The FTC publishes a plain CAN-SPAM compliance guide for business. Even an “educational” newsletter counts as commercial if it is promoting your services.
HIPAA shadows the whole channel. You cannot use protected health information for marketing without proper authorization, and that includes how you build and segment email lists. The same claim rules apply too: an email cannot say what your website cannot. Our guide to email marketing for regenerative medicine clinics covers the compliant setup in detail.
What this means for your practice: Hold your email to the same standard as the rest of your marketing, plus the CAN-SPAM basics, plus HIPAA care with patient data. The claim rules never relax just because the channel changed.
Now we can pull all four layers into one approach.
The Safe Harbor: Messaging That Satisfies Every Layer
A safe harbor message is one that satisfies the FDA, the FTC, the platforms, and the states all at once. The good news is that the four rulebooks point in the same direction. When you describe process instead of promising outcomes, you tend to clear all of them together.
Here is the pattern that holds up across every layer.
| Do This | Not This |
|---|---|
| Describe what PRP is and how the procedure works | Claim PRP treats or cures a condition |
| Frame the next step as a consultation | Promise results or assured improvement |
| Use honest, evidence-aware language | Overstate early or limited research |
| Keep reviews real and non-misleading | Use testimonials that imply typical cures |
| Add any state-required notice | Assume federal compliance is enough |
The unifying idea is restraint plus education. Take a phrase like “Schedule a consultation to learn whether PRP may be appropriate for you.” The FDA, the FTC, and the platforms can all live with it. It describes a process and invites a conversation. It does not promise an outcome, imply a cure, or directly promote a restricted treatment.
What this means for your practice: You do not need a different message for each rulebook. You need one honest, process-focused message that respects all of them. Education-first marketing is not a compliance compromise. It is the approach that happens to satisfy every layer at once.
How This Looks In Practice
Consider a regenerative medicine clinic preparing a new PRP marketing campaign across its website, Google Ads, and email. The owner wants the campaign reviewed against every layer before launch.
The Challenge: The draft copy promised “lasting relief” from joint pain, used a before-and-after image, and planned a Google ad headlined “PRP Treatment Available Now.” Each piece tripped a different rulebook.
The Approach: The clinic rebuilt the campaign around the safe harbor pattern. The website described the PRP process and invited consultations, with no outcome claims. The Google ad shifted to an educational angle pointing at a “What Is PRP?” resource. The email followed CAN-SPAM basics and dropped the results language. Where the clinic also marketed stem cell services, it added the state-required notice.
The Compliance Check: FDA layer, no disease-treatment language. FTC layer, no unsupported claims, reviews kept honest. Platform layer, no direct PRP promotion on Google, no before-and-after on Meta. State layer, required notice added where it applied.
The Result: The campaign launched without rejections or letters, because it was built to pass all four layers from the start, not patched after a problem.
Frequently Asked Questions
What can I legally say about PRP therapy in my marketing? You can describe what PRP is, how the procedure works, and invite a consultation. You cannot claim it treats or cures a condition, promise results, or overstate the research. Describe process, not outcomes.
What are the FDA rules for marketing PRP treatments? The FDA regulates the product, and your language can change how it is classified. Autologous, minimally manipulated PRP generally falls under the 361 pathway. Disease-treatment claims can push it toward 351 drug territory, which requires FDA approval you do not have.
Can I run Google or Meta ads for PRP therapy in 2026? Not as direct promotion. Google lists PRP as a speculative or experimental treatment and prohibits ads that promote it directly, though it allows educational content under conditions. Meta restricts health targeting, data use, and before-and-after imagery. Both are possible to work within, carefully.
What does the FTC require for PRP health claims? Truthful claims backed by competent and reliable scientific evidence before you publish. The bar for health claims is high, and overstating limited research is a common violation. If you cannot prove it, do not claim it.
What are the state advertising rules for PRP clinics? They vary by state. Some states add notice or disclosure requirements to regenerative marketing. Florida’s CS/CS/SB 1768, effective July 1, 2025, requires specific notices for stem cell therapy advertising, though that law targets stem cells, not PRP. Check your own state with counsel.
What are the email marketing compliance rules for PRP clinics? CAN-SPAM requires accurate sender and subject lines, a physical address, and an honored opt-out. HIPAA limits using patient data for marketing without authorization. And the same claim rules apply, so an email cannot say what your website cannot.
What is a safe harbor approach for PRP marketing? A single, honest, process-focused message that satisfies all four layers at once. Describe PRP and the procedure, invite a consultation, avoid outcome promises, keep reviews real, and add any state-required notice. Education-first marketing clears every rulebook together.
Does the 361 vs. 351 distinction really affect my marketing words? Yes. The classification turns partly on intended use, and your marketing signals intended use. Implying disease treatment can move the product into the drug category in the FDA’s eyes, regardless of what the product physically is.
Key Takeaways
- Four layers apply at once. FDA, FTC, ad platforms, and state law each govern a different part of PRP marketing.
- The FDA watches your words. Disease-treatment language can reclassify your product from 361 to 351.
- The FTC wants proof. Every health claim needs real evidence before you publish it.
- Platforms are a separate test. Google bans direct PRP promotion but allows education; Meta limits data, targeting, and imagery.
- State law can add rules. Notice and consent requirements vary, and Florida’s stem cell law shows how far they can reach.
- Email has its own rulebook. CAN-SPAM basics plus HIPAA care, with the same claim limits as everything else.
- Safe harbor is one message. Describe process, invite consultation, avoid promises. It satisfies all four layers together.
PS: Get Your PRP Marketing Reviewed
PS: Marketing PRP across four overlapping rulebooks is exactly the kind of thing that is easy to get wrong and expensive to fix. If you want your campaigns built to pass every layer from the start, that is what we do for regenerative medicine practices. Reach out at [email protected], or watch how we break down regen compliance on YouTube and subscribe for weekly insights.
About Regen Portal
Regen Portal is a marketing company serving the regenerative medicine industry. We provide SEO, content creation, social media management, paid advertising, website development, and branding services for clinics, manufacturers, distributors, and independent providers. Some strategies discussed in our educational content align with services we offer. For more on how we work, contact us.
Oscar Tellez is the founder of Regen Portal, a marketing company built for the regenerative medicine industry. With over 15 years of experience spanning clinical operations, product distribution, and digital marketing, Oscar has helped hundreds of practices, manufacturers, and distributors grow through compliant, high-performance marketing strategies. He holds a B.S. in Exercise Physiology and Health Promotion from Florida Atlantic University.
